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Abstract
Mental health problems constitute the largest single source of world economic burden, with an estimated global cost 
greater than cardiovascular disease, cancer or diabetes individually. In the European Union mental disorders affect mil-
lions of people and these numbers are expected to rise as result of Europe's ageing population. Given the biological 
causes of many of these disorders, most studies focus on their molecular basis. Bipolar disorder (BD) is characterized by 
mood swings between depression and mania resulting in cognitive and functional impairments that require lifetime 
treatment. Recurrent mood episodes, residual symptoms, functional impairment, psychosocial disability with high rates 
of divorce, unemployment, drug abuse and suicide attempting, and significant medical comorbidities such as metabol-
ic and cardiovascular diseases cannot be efficiently controlled even with proper use of current treatments. Moreover, 
delayed diagnosis/misdiagnosis is frequent because reliable biomarkers are absent. Therefore, a better understanding 
of BD pathophysiology is a prerequisite for the design of new drugs and their implementation in clinical practice as 
well as to develop biomarkers for a more accurate and earlier diagnosis and/or evaluation of therapeutic response. 
This review summarises the association between decreased cellular resilience towards stress and BD. Since the key 
stress-response mediator Mitochondria-Associated Membranes (MAMs) modulate several BD relevant processes such 
as mitochondrial dysfunction and oxidative stress, Ca2+ deregulation and cytoskeleton abnormalities, endoplasmic re-
ticulum stress responses, loss of proteostasis and inflammasome activation, we propose the “MAM hypothesis” for BD 
pathophysiology. Targeting MAM-associated signaling pathways can be a promising investigation avenue to identify 
novel therapeutic strategies.
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Bipolar Disorder
BD is a chronic psychiatric illness with a remitting course, 
affecting 2.4% of the general population [1], characterized 
by mood swings between manic and depressive states that 
result in cognitive and functional impairments, high health 
care costs and premature mortality [2,3]. 
BD is the sixth leading cause of disability worldwide 
responsible for loss of more disability-adjusted life-years 
than all forms of cancer and major neurological conditions 
[4]. BD is associated with greatly impaired quality of life 
and increased physical health burden [5]. Moreover, BD 
patients tend to have high rates of divorce, unemployment, 
drug abuse and crime as consequence of impaired social 
cognition, and its impact on patients can be devastating, 
with approximately 23% of patients with BD reported hav-
ing suicide attempts [6]. Moreover, individuals with BD 
diagnosis have a high risk of medical comorbidities such as 
metabolic (diabetes, obesity and metabolic syndrome) and 
cardiovascular disorders [7]. 
Current knowledge of BD's neurobiology and patho-
physiology is still modest [8] and with no clear biological 
markers available, early diagnosis is presently a great chal-
lenge to clinicians.
Pharmacological therapy is often the first-line treat-
ment for BD, followed by psychological [9] and psychoso-
cial interventions [10]. For maintenance pharmacological 
treatment the main goal is to prevent recurrences of mood 
episodes, using mood stabilizers (e.g. lithium, valproate, la-
motrigine and carbamazepine) and atypical antipsychotics 
(e.g. olanzapine, aripiprazole, quetiapine and risperidone) 
or conventional antidepressants for depressive phases 
(e.g. selective serotonin reuptake inhibitors or bupropi-
on) [11]. Psychosocial treatments include individual psy-
chotherapies, supportive group therapies, education about 
the disease and focus on treatment adherence and self-care 
[12]. Furthermore, polypharmacy is still common in BD 
treatment, reflecting the gap between research and clinical 
practice. Currently available drugs are primarily targeted 
at relieving symptoms, are often only partially effective 
and have significant side effects. Thus, a better under-
standing of the underlying pathophysiological mechanisms 
to identify potential therapeutic targets is a prerequisite for 
the design of new drugs as well as to develop biomarkers 
that help in a more accurate and earlier diagnosis and/or to 
evaluate therapeutics response. 
Impaired cellular resilience
A growing body of evidence suggests that mood disorders 
are associated with regional atrophic brain changes that 
may be closely associated with abnormalities in cellular 
plasticity, including the resilience of brain cells to resist or 
adapt to environmental stressors [13]. Structural neuroim-
aging and postmortem studies have highlighted anatomi-
cal and neuropathological alterations in BD patients such 
as ventricular enlargement, decreased levels of neuronal 
integrity markers and reduction of neuronal density in 
specific brain areas, suggesting abnormalities in the cellu-
lar resilience towards stressful conditions of neurons and 
glia cells [14]. These alterations can explain several clinical 
features such as the progressive shortening of inter-epi-
sode interval with each recurrence occurring in consort 
with reduced probability of treatment response as the ill-
ness progresses. This hypothesis is supported by recent 
genetic studies in postmortem prefrontal cortex samples, 
which identified the EGR3 regulatory unit (regulon) that 
translates environmental stimuli into long-term changes 
in the brain to be robustly repressed in BD patients [15], 
further suggesting that an impaired response to stress in-
fluences BD risk. 
Cellular modeling in BD using lymphoblastoid cell 
lines, fibroblasts, olfactory neuronal epithelium and neu-
rons reprogrammed from induced pluripotent stem cells 
(iPSCs) [16-18], has proven useful to understand its bio-
logical basis, and potential pathways have been identified, 
especially in cellular resilience-related mechanisms. The 
most replicated findings that show consistency with ge-
nome-wide association studies (GWAS), brain-imaging 
and post-mortem brain expression include abnormalities 
in endoplasmic reticulum (ER)-related stress respons-
es, mitochondrial function and Ca2+ signaling, which are 
often reversed in vitro with lithium. Furthermore, pa-
tient-derived cellular models also support that alterations 
in microRNAs (miRNAs), glia and immune cell signaling, 
cytoskeleton as well as oxidative stress, inflammasome ac-
tivation, autophagy and apoptosis play a relevant role in 
BD pathophysiology [8,19-29]. 
ER-mitochondria miscommunication
The above BD-related events are associated with func-
tions localized to a subdomain of the ER, known as mito-
chondria-associated membranes (MAMs), which are lipid 
raft-like domains closely opposed to mitochondria in such 
a way that the two organelles can physically and biochem-
ically communicate with each other. ER-mitochondria 
juxtaposition is crucial for efficient inter-organelle Ca2+ 
transmission controlling mitochondrial bioenergetics and 
pro-survival/pro-death pathways and determining cell 
fate under stressful conditions [30, 31]. The last few years 
have been marked by increased research on the molecular 
structure and function of MAMs, which provided a greater 
knowledge of the structural proteins dynamically associat-
ed with the ER-mitochondria contacts under physiological 
and non-physiological conditions. MAMs functions elu-
cidation allowed to understand that MAMs role is much 
more important than it would be anticipated. MAMs are 
responsible for regulating mitochondrial shape and motil-
ity, as well as bioenergetics and redox status. Besides that, 
MAMs have a central role in the modulation of several key 
processes for cell survival, such as ER stress, autophagy, 
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inflammasome signaling and apoptosis [32]. MAMs com-
position and abundance are highly dynamic being modu-
lated by metabolic demands and cellular insults in order 
to adapt to different conditions. Under acute or chronic 
ER stress normal ER-mitochondria cross-talk is affect-
ed and this circumstance may cause several dysfunctions, 
such as metabolic impairment, changes in redox balance 
and cell death control, which, in turn, may be the source 
of various central nervous system (CNS) disorders where 
ER stress plays a central role [33,34] and as a consequence 
of that develop morphological and biochemical alterations 
in MAMs [35]. Therefore, changes of the ER-mitochon-
dria axis could be responsible for the onset and progression 
of several diseases, including cancer, diabetes, obesity and 
neurodegenerative disorders [33]. Sigma-1 receptor (Sig-
1R), an intracellular chaperone that resides specifically at 
the ER-mitochondria interface, modulates inter-organelle 
Ca2+ signaling [36]. Beyond these functions, MAM-res-
ident Sig-1R is also important to trigger and to fit an-
ti-stress responses. Under stress conditions, this receptor 
promotes passage of stress signals from the ER to the nu-
cleus through its interaction with various receptors such 
as the N-methyl-D-aspartate receptors (NMDARs), ion 
channels, kinases and numerous regulatory key proteins 
residing on ER, MAM, nucleus or in the cytosol. Based 
on these complex intracellular actions the Sig-1R has been 
conceptualized as a pluripotent modulator in living sys-
tems with pleiotropic protective effects. Recent studies 
found that the Sig-1R regulates bioenergetics, free radical 
generation, oxidative stress, unfolded protein response 
(UPR) and cytokine signaling, as well as morphogenesis 
of neuronal cells, such as neurite outgrowth, synaptogen-
esis, and myelination, which can be disturbed by cellular 
stress [37]. Their activation may therefore control a vari-
ety of stress-related cellular systems, thus contributing to 
a cellular defense system that protects the nervous system 
against chronic stress. In the last two decades, a consider-
able amount of clinical data demonstrated the role of Sig-
1R in various pathologies. In particular ample evidence 
including the presence of genetic variants within SIG-
MA1R and the interaction of numerous antidepressants 
with these receptors, suggested a role of Sig-1R in affective 
disorders [38,39]. Accordingly, a genetic polymorphism is 
a risk factor for schizophrenia and Sig-1Rs levels are sig-
nificantly reduced in the brain of schizophrenic patients 
[40]. Currently, some drugs (e.g., fluvoxamine, fluoxetine, 
escitalopram, donepezil, ifenprodil), which have been used 
in humans, and some endogenous neurosteroids (e.g. de-
hydroepiandosterone) have high to moderate affinity to 
Sig-1R and exert antidepressant-like and neuroprotective 
actions supporting their clinical implication in numerous 
neuropsychiatric diseases [38]. The significant advanc-
es in Sig-1R research can be translated into future phar-
macological approaches able to control the cellular stress 
systems based on a better understanding of upstream and 
downstream intracellular signaling cascades [41].
The above evidences support the “MAM hypothesis” 
for BD pathophysiology (Figure 1), which considers that 
ER-mitochondria miscommunication at MAMs is an ini-
tial event leading to diminished cellular resilience to stress-
ful conditions and that approaches targeting these specific 
inter-organelle structures can lead to new treatment strat-
egies and early diagnosis biomarkers. This novel hypothe-
sis is supported by studies demonstrating modifications of 
several MAM-modulated cellular processes in BD patients, 
namely Ca2+ dyshomeostasis and cytoskeleton abnormal-
ities, changes in the ER stress responses, mitochondrial 
dysfunction and oxidative stress, proteostasis (autophagy) 
impairment and inflammasome activation. 
Ca2+ dyshomeostasis and cytoskeleton 
abnormalities
Over the last few years, several studies have identified 
common single polymorphisms (SNPs) in calcium volt-
age-gated channel subunit alpha 1C (CACNA1C) and 
ankyrin-3 (ANK3) in BD patients, implicating these as 
susceptibility genes for BD [42,43]. These findings sup-
port that Ca2+ deregulation is involved in BD pathophysi-
ology, as both CACNA1C and ANK3 encode Ca2+ signal-
ing-related proteins: Cav1.2 Ca2+ channel are important 
regulators of Ca2+ influx into cells stimulated by ER Ca2+ 
depletion and are critical for normal brain development 
and plasticity [44,45] and ankyrin directly interacts with 
the ER 1,4,5-inositol triphosphate receptor (IP3R), which 
is localized at MAMs and is responsible for ER Ca2+ re-
lease [46]. Carriers of the CACNA1C risk polymorphism 
rs1006737 exhibit greater age-related thickness of cortical 
brain areas widely associated with mood regulation in BD 
[47]. Furthermore, recent studies demonstrate that the 
genetic variation rs10761482 of the ANK3 gene affects 
age-related brain atrophy [48]. Bioinformatics analysis of 
differentially expressed proteins identified by proteomics 
in postsynaptic density from the anterior cingulate cortex 
of BD patients further implicated changes in Ca2+ signal-
ing in BD pathophysiology [49]. Accordingly, L-type Ca2+ 
channel (LTCC) antagonists have been used in BD for over 
30 years without becoming an established therapeutic ap-
proach, however, additional genetic, molecular and phar-
macological data are required to improve the selectivity, 
efficacy and tolerability of LTCC antagonists [50]. 
Neurons derived from individuals with mutations and 
deficiencies in odd Oz/ten-m homolog 4, TENM4 (ODZ4) 
genes show abnormal characteristics [51]. ODZ4, a human 
homolog of the Drosophila pair-rule gene ten-m (odz), 
encodes teneurin, a transmembrane protein that organizes 
the cytoskeleton [52], a crucial event for ER-mitochondria 
contact and Ca2+ transfer [53]. Recently, by profiling the 
proteomics of BD-hiPSC-derived neurons, data obtained 
by Tobe and colleagues implicate aberrant posttranslation-
al modification of collapsin response mediator protein-2 
(CRMP2), a cytoskeleton-binding protein that is pres-
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Figure 1. The “Mitochondria-Associated ER Membrane (MAM) Hypothesis” for BD pathophysiology. Patient’s cells are chronically ex-
posed to stressful conditions leading to MAMs disruption and subsequent perturbation of cells’ ability to cope with stress (cellular resilience), which 
arises from loss of proteostasis, changes in lipid and calcium homeostasis, dysregulation of intercellular communication, impairment of ER stress 
responses, mitochondrial dysfunction and oxidative stress, formation of inflammasome and induction of apoptosis, which all have been described 
in BD. Impairment of these MAM-regulated events decreasing cellular resilience can explain several BD outcomes namely its progressive nature, the 
functional outcome, the physical complications and also the therapeutic implications, supporting MAMs as promising therapeutic targets for BD.
ent particularly in dendritic spines, in abnormal Ca flux 
[27]. Evidence from clinical studies and animal models 
supports that disturbed microtubule cytoskeleton under-
lie abnormalities in neuronal cell architecture, namely in 
dendritic complexity and synaptic density changes, which 
disrupt synaptic connectivity, in the brains of subjects with 
mood disorders such as BD [54]. Aberrant microtubular 
organization in patients with BD might arise from dimin-
ished microtubule-associated proteins expression, which in 
turn may affect Ca2+ voltage-activated currents [55]. Ge-
nome-wide association data from the Psychiatric Genomics 
Consortium suggests that deregulation of cytoskeleton re-
modeling, in particular of actin cytoskeleton, which has di-
rect impacts on endocytosis, phagocytosis, exocytosis, vesi-
cle trafficking, neuronal maturation and migration, neurite 
outgrowth and synaptic density and plasticity, is implicated 
in BD [56]. A recent study shows that the genetic deletion 
in mice of neural abelson-related gene-binding protein 2 
(nArgBP2), which interacts with the postsynaptic scaffold-
ing proteins SAP90/PSD95-associated protein 3 (SAPAP3) 
and SH3 and multiple ankyrin repeat domains 3 (Shank3 )
that are implicated in the pathogenesis of various mood dis-
orders, including BD, leads to manic/bipolar-like behavior 
resembling symptoms of BD by controlling actin dynamics 
that causes a robust and selective inhibition of excitatory 
synapse formation [57].
Compromised ER stress response
The ER consists of a large membranous network and is 
the cellular site for synthesis, folding, and maturation of 
most secreted and transmembrane proteins. It has many 
different functions including the translocation of proteins 
across the ER membrane, the integration of proteins into 
the membrane, the folding and modification of proteins in 
the ER lumen, the synthesis of phospholipids and steroids 
on the cytosolic side of the ER membrane, and the storage 
of Ca2+ ions in the ER lumen and their regulated release 
into the cytosol [19,33]. Lately, ER has been put forward as 
a key organelle in inducing chronic stress associated with 
many brain disorders including neuropsychiatric diseases 
such as BD [58].
ER stress is caused by the accumulation of unfolded and 
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ER homeostasis. ER stress activates a signaling cascade 
called the UPR, which triggers a set of transcriptional and 
translational events that restore ER homeostasis, promot-
ing cell survival and adaptation [59,60]. If this adaptive re-
sponse fails, a terminal UPR program commits such cells 
to apoptosis [61]. The outcomes of the cellular response 
are influenced by ER stress levels [62]. When ER stress is 
mild, the cell can recover and adapt. However, when ER 
stress is prolonged or too severe, these mechanisms fail to 
restore proteostasis leading to autophagy and apoptosis 
if the stress cannot be alleviated. Canonical mammalian 
pathways of the UPR pathway involve three specialized ER 
stress-sensing proteins: protein kinase R-like endoplasmic 
reticulum kinase (PERK), inositol-requiring enzyme 1 α 
(IRE1α) and activation of transcription factor 6 (ATF6) 
[63]. In cells undergoing ER stress, the ER chaperone, 
glucose-regulated protein 78 (GRP78) dissociates from 
the ER transmembrane sensors [64] and promotes their 
activation, thus inducing phosphorylation and oligomer-
ization of IRE1α and PERK, as well as the translocation 
of ATF6 to the Golgi where it is cleaved by Site 1 and Site 
2 proteases (S1P and S2P) [63]. Active IRE1α processes 
mRNA encoding for X-box binding protein 1 (XBP1), a 
transcription factor that up-regulates genes that encode 
mediators of the ER-associated degradation (ERAD) 
pathway, organelle biogenesis and protein quality control 
[65]. PERK activation reduces protein load in the ER by 
decreasing general protein synthesis through phosphory-
lation of the α-subunit of eukaryotic translation-initiation 
factor 2α (eIF2α), which paradoxically increases selective 
translation of activating transcription factor 4 (ATF4) 
mRNA [66]. ATF4 is a member of the bZIP family of 
transcription factors that activates expression of several 
UPR target genes involved in antioxidant responses, such 
as the transcription factor Nrf2, apoptosis and autophagy 
[67,68]. In cells experiencing ER stress, ATF6 is cleaved 
at the Golgi apparatus allowing the newly released cytoso-
lic domain to translocate to the nucleus where it regulates 
ER chaperones, ERAD-related genes, and proteins in-
volved in organelle biogenesis [69]. Severe and/or chronic 
ER stress can have, however, negative effects leading to 
apoptosis through different pathways such as: the rise of 
reactive oxygen species (ROS) and Ca2+ levels, activation 
of the ER-resident caspase-12 (in rodents or caspase-4 in 
humans), CAAT/enhancer binding protein homologous 
protein (CHOP) or c-Jun NH2-terminal kinase (JNK) [70]. 
Several evidences highlight the role of ER-related stress 
response in BD. For instance, the fact that the expression 
of the BiP protein (GRP78 protein / glucose-regulated 
protein, 78 kDa), a chaperone that is highly expressed in 
the ER, can be up-regulated by different types of mood 
stabilizers, allowed to hypothesize that the ER, an organ-
elle that has been described to be implicated in the cellu-
lar response to different forms of cellular stress, may be 
involved in the pathophysiology of BD. Lately, evidence 
emerged revealing that lithium and valproic acid (VPA), 
drugs widely used in the treatment of BD, increase the 
expression of ER chaperones and activate the unfolded 
protein response element (UPRE), suggesting that their 
mode of action includes UPR activation [71]. Further-
more, genetic association studies have given an import-
ant contribution in order to strengthen this hypothesis by 
demonstrating significant association of GRP78 promotor 
polymorphisms with BD and linkage between other ER-
stress associated genes like XBP1 (X-box binding protein 
1) or GRP94 (glucose-regulated protein, 94 kDa, synonym 
for heat shock protein HSP90B1) and BD pathology [21]. 
XBP1, a pivotal gene in the ER stress response, has been 
considered a genetic risk factor for BD and a polymor-
phism in its promoter was found less effective to reduce 
ER stress in BD patients-derived cells [72]. Also, changes 
in the levels of several ER UPR-related proteins have been 
described in BD. In healthy controls but not in BD patients 
it was found an increase in the levels of GRP78, eIF2α-P, 
and CHOP after ER stress induction, which represents a 
cellular response to inhibit global protein synthesis and, 
therefore, functions as a defense mechanism triggered to 
cope with stress and restore ER homeostasis [19]. Tuni-
camycin-induced cell death was found significantly higher 
in patients compared to controls and, more importantly, 
early-stage patients did not differ from controls while the 
late-stage patients showed an impaired ER stress response 
[19]. These findings are in accordance with the “MAM 
hypothesis” for BD pathophysiology (Figure 1), which hy-
pothesizes that ER-mitochondria miscommunication at 
MAMs is an initial event diminishing cellular resilience 
to stressful conditions in BD patients. Patients presenting 
Darier’s disease with a mutation in the ER Ca2+ pump SER-
CA have high rates of comorbid BD and/or the presence of 
manic-like symptoms [73] further supporting deregulated 
ER stress responses in BD. Moreover, a Bcl-2 polymor-
phism was shown to contribute to Ca2+ dyshomeostasis in 
BD through direct regulation of ER IP3R and Bcl-2 knock-
out mice have increased anxiety-like behaviours [74]. Ac-
cordingly, deregulation of Ca2+ signaling is one of the most 
reproducible observations in BD and is supported by the 
alteration of transcripts involved in Ca2+ signaling in iPSCs 
from BD patients [22]. Finally, Disrupted-In-Schizophre-
nia 1 (DISC1), a genetic candidate for BD, also modulates 
transcriptional responses to ER stress [75].
Mitochondrial dysfunction
Mitochondria are small organelles that play a central role 
in cell metabolism because they are the main energy pro-
viders by converting metabolites to adenosine-5-triphos-
phate (ATP). Based on the chemiosmotic theory, most of 
the ATP produced by ATP synthase arises from the elec-
trochemical gradient generated by the electron transport 
chain across the inner membranes of mitochondria [76]. 
Furthermore, mitochondria are also key organelles in di-
verse pathophysiological contexts, such as the regulation 
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of free radicals production, Ca2+ homeostasis and redox 
signaling, and also take part in the intrinsic pathway of 
apoptosis [76,77]. Besides that, mitochondria are involved 
in modulation of neuronal activity, neuroplasticity and 
morphogenesis because their distribution and activity are 
key factors for the normal neuronal development and syn-
aptic plasticity. For instance, they control the neurotrans-
mitter’s exocytosis and ion homeostasis in presynaptic 
nerve terminals [76,78].
There is increasing evidence showing that mitochon-
drial dysfunction is implicated in different diseases, such 
as cardiovascular diseases, neuromuscular neuropathies 
and neurodegenerative and neuropsychiatric disorders 
[76]. Impaired mitochondria function can arise from mu-
tations or polymorphisms of mitochondrial DNA (mtD-
NA), deregulation of free radicals production leading to 
oxidative stress, impaired phospholipid metabolism and 
glycolytic shift, ATP synthesis decrement and changes in 
Ca2+ homeostasis, which were already implicated in mood 
disorders [76,77]. Kato and Kato were the first to propose 
the mitochondrial dysfunction hypothesis for BD based 
on the presence of mtDNA abnormalities and amino acid 
substitutions in specific candidate genes in BD patients, 
such as the mtDNA polymorphisms 5178C and 10398A; 
they found that these abnormalities were associated with 
decreased brain intracellular pH and alteration of intracel-
lular Ca2+ signaling, respectively [79]. Numerous evidences 
that emerged recently support that impaired mitochondri-
al function is associated with mood disorders and in partic-
ular with BD [76,77,80,81].
Multiple lines of evidence suggest that mood abnor-
malities arising from alterations of mitochondria and en-
ergy production are a key feature in the pathophysiology 
of BD [82]. Evidence of mitochondrial dysfunction in BD 
includes decreased levels and activity of nuclear-encod-
ed subunits of mitochondrial respiratory complexes, de-
creased pH and altered oxidative phosphorylation in the 
brains of BD patients [83]. Elevated lactate levels in BD pa-
tient's brain suggest a shift from aerobic to anaerobic me-
tabolism, further supporting mitochondrial dysfunction in 
BD [82]. Changes in the expression of mitochondria-relat-
ed genes also corroborate the mitochondrial impairment 
in BD. Maeda and colleagues [84] showed a decrease in 
DISC1 expression in lymphoblasts with the DISC1 risk 
haplotype for BD, when compared to lymphoblasts from 
control subjects. Scola and colleagues demonstrated that 
patients with BD have a differential gene expression that 
increases the sensitive towards dysfunction of the elec-
tron transfer process [85]. The NDUFV2 gene, which is 
required for the first step in the electron transfer process, 
NDUFS8, which controls the electron relay, and NDUFS7, 
which is responsible for the reduction of ubiquinone to 
ubiquinol, are down-regulated in BD patients. Later on, an 
up-regulation of NDUFV2 was detected in depressed state 
when compared with euthymic state [86]. Yoshimi and 
colleagues obtained additional evidences corroborating 
the theory of mitochondrial dysfunction in BD. Through 
metabolomic assays of cerebrospinal fluid (CSF) obtained 
from BD patients, they observed that deregulation of isoc-
itrate metabolism in the mitochondrial citric acid cycle is 
relevant in the pathogenesis of BD [87]. Moreover, mito-
chondrial dysfunction has been identified as the cause of 
the neuroprogression and cognitive impairment observed 
in BD. As mentioned above, brain mitochondria are essen-
tial for neurotransmission and neuronal plasticity, includ-
ing long-term potentiation induction, which is required 
for cellular resilience under stress conditions and behav-
ioral adaptation. Therefore, mitochondrial dysfunction 
will consequently lead to cellular resilience alterations, 
which play a major role in BD [77]. Mood stabilizers are 
used to treat BD because they have modest antidepressant 
properties and avoid the recurrence of new mood episodes 
[88]. Recently, several studies clarified the mechanisms of 
action of these stabilizers, revealing that they affect mito-
chondrial function [77]. 
Taken together, the above evidence allowed to face 
mitochondrial dysfunction as the most robust alteration 
found in the postmortem BD brain [77].
According to the MAM hypothesis, communication 
between ER and mitochondria at MAMs level is required 
to regulate cell homeostasis and allow maintenance of cel-
lular resilience under stress conditions. Thus, if both mito-
chondrial integrity and function are impaired this commu-
nication will be affected, and the downstream events will 
be compromised.
Oxidative stress
A cell is in an oxidative stress state when an imbalance 
between the production of ROS and antioxidant activities 
occurs [89]. Mitochondria, in addition to be the major en-
ergy source of the cells, are also considered the main origin 
of ROS since superoxide radical is generated as a conse-
quence of the electron transport chain, which may give rise 
to oxidative stress and subsequent cell damage. As result 
of accumulation of oxidative lesions, several physiological 
functions can be affected, increasing disease’s incidence 
concomitantly with a reduction in life span [90]. Despite 
the physiologic relevance of low and intermediary ROS 
levels that preserve cell survival [91] oxidative stress has 
been faced as a potential unifying mechanism contributing 
to several human pathologies since high ROS concentra-
tions, above the clearance capacity of the cell cause oxi-
dative stress, mitochondrial dysfunction, cellular damage, 
and, in numerous cases, cell death [92]. Accordingly, in-
creasing evidence suggests the involvement of oxidative 
stress in the pathology and progression of BD and several 
studies report the increase in the levels of oxidative stress 
markers in BD patients [26,77]. Lipid peroxidation and ni-
tric oxide levels were shown significantly increased in red 
blood cells or serum from BD patients compared to healthy 
controls [93,94] and increased protein oxidation and ni-
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tration was detected in synaptosomes and mitochondria 
isolated from patients’ postmortem prefrontal cortex [95]. 
4-hydroxy-2-nonenal (HNE), which is considered a strong 
marker of oxidative stress that leads to the formation of 
HNE-protein adducts able to alter cellular homeostasis and 
cause the development of a pathological state, was found 
in the cortex of bipolar patients [96]. Oxidative damage 
of nucleic acids was also observed and was found to be 
increased in peripheral and post-mortem patient brain 
samples [93,94,97,98]. However, contradictory data on 
the activities of antioxidant enzymes such as superoxide 
dismutase, catalase and glutathione peroxidase was report-
ed in BD patients [94]. Recent evidences support that the 
cellular effects of oxidative stress worsen with time and 
number of manic episodes. Despite unchanged levels of 
the main cerebral antioxidant glutathione were found in 
the anterior cingulate cortex of BD patients in compari-
son with healthy controls [99], Rosa and collaborators, 
using blood samples from patients with different ages of 
disease onset, showed that glutathione levels are lower in 
BD patients and observed a negative correlation with the 
age at onset [100]. In addition, higher protein carbonyl 
and lipid hydroperoxide content were determined in adults 
compared to adolescents with BD [101] and the increased 
levels of an early component of the peroxidation chain in 
euthymic older patients with BD support the hypothesis of 
a persistent effect of ROS in patients with BD into late life 
[102]. It was observed in a recent exploratory study that 
the plasma levels of oxidative stress markers were lower in 
adolescents with fully syndromal BD than controls, while 
levels in the at-risk groups were between healthy controls 
and fully syndromal BD supporting a role of oxidative stress 
in BD risk progression [103]. Furthermore, Andreazza 
and colleagues observed that superoxide dismutase activ-
ity was higher in manic and depressed patients compared 
to euthymic patients and controls [104]. Of relevance, the 
antioxidant properties of numerous mood stabilizers were 
described [105-110].
Proteostasis (autophagy) impairment
Protein misfolding and aggregation have been described 
as relevant events in many neurodegenerative and neuro-
psychiatric diseases [111]. The majority of neuropsychi-
atric diseases, such as schizophrenia, BD, depression and 
autism are associated with variations in the DISC1 gene 
that is expressed in neuronal dendritic spines controlling 
spine and synapse development. These variations seem to 
promote DISC aggregation since dimers, octamers, high-
er oligomers and insoluble aggregates of DISC1 have been 
identified in some of these chronic illnesses. The formation 
of DISC1 aggregates was recently associated with a decrease 
in free soluble protein and a gain of toxic function leading 
to the impairment of mitochondrial axonal transport [111]. 
Thus, the occurrence of certain mutations can trigger the 
accumulation of misfolded proteins, which might lead to 
the formation of protein aggregates [34,111] that can affect 
several mechanisms, such as mitochondrial function, slow-
ing axonal transport and promoting oxidative stress [111].
Proteostasis, which means regulated protein homeo-
stasis, is a complex process that requires the dynamic co-
ordination between efficient folding of newly synthesized 
proteins, quality control and degradation mechanisms to 
reduce the load of unfolded and/or misfolded proteins to 
prevent abnormal protein aggregation [34]. Chaperones 
are central players in proteostasis maintenance since they 
are responsible for protein folding in cells, acting as an ef-
fective first line defense against protein misfolding through 
the recognition of non-native conformations of polypep-
tides that are sent for refolding. When this protective 
mechanism, which allows recovering the native confor-
mation of proteins, fails degradation pathways —ubiquitin 
proteasome pathway (UPS) and autophagy—are activated. 
UPS and lysosomal autophagic degradation pathways are 
complementary in their mode of action, acting as a second 
barrier to restore proteostasis. When the proteasome is 
defective or saturated, or if there is an excess of ROS, the 
accumulation of misfolded proteins occurs leading to the 
formation of both toxic soluble oligomers and larger aggre-
gates that can then be eliminated by autophagy [34,111]. 
However, in several neurodegenerative disorders such as 
Parkinson's disease and amyotrophic lateral sclerosis, auto-
phagic vacuoles (autophagosomes or autophagolysosomes) 
accumulate suggesting lysosomal dysfunction. Due to the 
impairment of the autophagic pathway, misfolded protein 
and aggregates are not cleared from the cells resulting in 
cell death [111].
Lithium, a classic mood stabilizer, was also proposed 
for treatment of Huntington’s disease (HD) and ALS be-
cause it was shown to be able to induce autophagy. In 
combination with two other mood-stabilizing and anti-
convulsant drugs, VPA and carbamazepine (CBZ), lithium 
was suggested to induce autophagy through inhibition of 
inositol monophosphatase (IMPase), an enzyme that cat-
alyzes the hydrolysis of inositol monophosphate into free 
inositol [111,112]. The fact that lithium is a drug widely 
used in the treatment of BD, together with the evidence 
showing that patients with neurodegenerative disorders - 
where it has already been demonstrated the impairment in 
autophagy - exhibit several neuropsychiatric comorbidities 
like depression and apathy, anticipate autophagy deregu-
lation in BD. According to this evidence, an increment in 
autophagy could be beneficial in BD treatment. However, 
it is important to take into account that these are indirect 
evidences, indicating that further studies are required. 
Inflammasome activation 
The majority of diseases, namely brain diseases, have been 
associated with an important inflammatory component 
[113]. Inflammation is a protective immune response trig-
gered by the immune system in response to harmful stimu-
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li, such as pathogens, dead cells or irritants. Immune activa-
tion within the CNS occurs to aid repair and regeneration of 
tissues, hence preventing cell death. However, it can often 
contribute enhancing neuronal damage. Thus, the inflam-
matory response in the CNS may have both neuroprotec-
tive and deleterious effects, depending on the circumstanc-
es [113,114]. The innate immune system is the first to be 
activated to trigger an immunologic response and it acts 
through sensing of pathogen-associated molecular patterns 
(PAMPs) derived from invading pathogens, and danger-as-
sociated molecular patterns (DAMPs) [115]. In the CNS, 
pattern-recognition receptors are primarily expressed by 
microglia, macrophages, and astrocytes. Microglia cells are 
often termed the "sentinel of brain parenchyma" because 
they are constantly in a state of alert to detect pathogen's 
invasion through the pattern-recognition receptors (PRR) 
that they express [116]. They can display two different types 
of receptors: Toll-like receptors (TLRs) that are membrane 
spanning receptors, and Nod-like receptors (NLRs), which 
are cytoplasmic sensors able to oligomerize and form a plat-
form for the inflammasome [115,117].
Inflammasomes are cytosolic multimolecular com-
plexes that need to be activated to initiate and sustain the 
inflammatory response and they are formed by microglia 
and macrophages within the §CNS [114,115]. They are 
usually constituted by three main components: a cytosolic 
pattern-recognition receptor, the enzyme caspase 1 and an 
adaptor protein, apoptosis-associated speck-like protein 
containing a CARD (ASC), that facilitates the interaction 
between the former components. According to the vari-
able amino-terminal domain displayed, there are several 
subfamilies within the NLR family. Whereas members of 
the NLRP subfamily carry an N-terminal pyrin domain 
(PYD) that interacts with the pyrin domain of ASC to 
bridge the complex to pro-caspase-1, the NLRs contain-
ing a caspase activation and recruitment domain (CARD) 
bind directly to pro-caspase 1. The inflammasome assem-
bly leads to caspase-1 activation that converts the cytokine 
precursors pro-IL-1β and pro-IL-18 into mature and bio-
active form IL-1β and IL-18, respectively, which are two 
pro-inflammatory cytokines involved in neuroimmuno-
modulation, neuroinflammation and neurodegeneration. 
These cytokines trigger signaling cascades that culminate 
in a type of inflammatory neuronal death termed pyro-
ptosis [114,115,117,118]. There are two well-established 
pathways for NLRP3 inflammasome activation and an al-
ternative NLPR3 inflammasome activation pathway was 
recently described that occurs exclusively in human mono-
cytes [115,118,119].
Strong evidence has emerged implying the involve-
ment of inflammasomes in the initiation or progression 
of diseases with a high social and health impact, such as 
metabolic disorders and neurological diseases, includ-
ing meningitis, stroke and Alzheimer's disease [114,115]. 
Furthermore, activation of the immune system has been 
consistently reported in BD [120,121] and in the last few 
years, evidence has been emerged implying activation of 
the NLRP3 inflammasome in BD pathophysiology [17]. 
Altered levels of inflammatory cytokines were shown in 
the brain and periphery of patients with BD, suggesting 
that activation of the inflammatory system may play a role 
in the pathophysiology of BD [120]. Recent studies suggest 
that mitochondrial production of ROS may be linked to in-
flammatory activation. In fact, increased ROS production 
in result of inhibition of complex I of the mitochondrial 
respiratory chain led to increased levels of inflammatory 
factors such as IL-1, caspase 1, and NF-B and was recently 
linked to activation of an inflammatory redox sensor, the 
NLRP3. Post-mortem analysis of frontal cortex from BD 
patients showed lower levels of complex I and NDUFS7, 
a subunit of complex I, concomitantly with higher levels 
of mitochondrial NLRP3 and ASC and increased levels of 
caspase 1, IL-1β, IL-6, TNFα and IL-10 [17], suggesting 
that brain immune-activation in patients with BD is as-
sociated with mitochondrial dysfunction and NLRP3-in-
flammasome activation. Because inflammasome activation 
is recognized as a regulatory function associated with the 
specific membranous ER-mitochondria microdomains 
[122] a link between interorganelle miscommunication 
and NLRP3 activation in BD can be anticipated. Recently, 
it was found that genetic deficiency in vitro of caspase-1 
decreased depressive- and anxiety-like behaviors and pre-
vented the exacerbation of depressive-like behaviors fol-
lowing chronic stress [123] . This linkage is also supported 
by the fact that the induction of an inflammatory response 
in other neuropsychiatric diseases requires inflammasome 
activation [115]. Finally, Haneklaus and colleagues demon-
strated that both NLRP3 inflammasome formation and IL-
1β production are regulated by microRNAs that have been 
implicated in BD pathophysiology [124].
Intercellular communication mediated by 
microRNAs
MicroRNAs (miRNAs) are a class of endogenous, small, 
non-coding RNAs that post-transcriptionally regulate 
gene expression and are highly expressed in the brain, 
which have emerged as essential regulators of neuronal 
development, differentiation, and neuroplasticity [125] 
miRNAS are present in tissues and in circulating fluids, 
particularly in the blood and several reports highlight dif-
ferences of composition in disease states [126]. A periph-
eral blood compartment that may be particularly relevant 
are the exosomes, cellular miRNAs-containing secretory 
vesicles able to attach recipient cells and release miRNAs 
potentially modulating their function [127]. Recent results 
clearly indicate that miRNAs are important mediators of 
stress responses and their deregulation has been implicated 
in a variety of stress-related neuropathological conditions 
[128,129]. Accordingly, UPR regulates the expression of 
many miRNAs that play an important role in the regulation 
of life and death decisions during ER stress [130]. There is 
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accumulated evidence linking deregulation of numerous 
miRNAs with neuropsychiatric disorders, including BD. 
The problem of multiple susceptibility genes of small ef-
fect in BD has led to an increased interest in miRNAs. The 
mood stabilizer VPA used for treatment of BD has been 
shown to induce proteasomal degradation of Dicer, which 
causes a general down-regulation of miRNA expression, 
suggesting that VPA have some influence on BD psycho-
pathology through the modification of miRNA biogene-
sis [131]. Evidence from postmortem cortical brain tissue 
from affected individuals, as well as from BD patient-de-
rived neuronal cultures generated by reprogramming of 
human fibroblasts into iPSCs subsequently differentiated 
into neurons, demonstrate the deregulation of specific 
miRNAs in BD compared to control subjects [20]. Some 
of these miRNA, such as miR-34a, directly target the BD 
risk genes ANK3 and voltage-dependent L-type calcium 
channel subunit beta-3 (CACNB3) and modulate neuronal 
differentiation, expression of synaptic proteins and neuro-
nal morphology [28]. Genome-wide analysis followed by 
target gene and pathway analysis of brain-expressed miR-
NAs support that miR-499, miR-708 and miR-1908 genes 
and their targets may be implicated in the development of 
BD [29]. MiR-499 regulates mitochondrial dynamics and 
apoptotic pathways involving the Ca2+-dependent protein 
phosphatase calcineurin [132]. and the risk gene for psy-
chiatric disorders CACNB2.51 is a miR-499 target gene 
[29]. Recent pathway analysis also indicates a potential 
role of miR-499 in the regulation of the actin cytoskeleton 
[29]. that is crucial for neuronal cell migration and matura-
tion, neurite outgrowth and maintenance of synaptic den-
sity and plasticity. The miRNA miR-708 is located in the 
first intron of ODZ4, a human homolog of the Drosophila 
pair-rule gene ten-m (odz), which has been reported as a 
genome-wide significant susceptibility gene for BD. It was 
recently found that miR-708 regulates the expression of 
neuronatin, which is a membrane protein in the ER, and 
neuronatin-mediated regulation of intracellular Ca2+ levels 
has been implicated in cell migration and neural induction 
within embryonic stem cells [133]. MiR-1908 was showed 
to belong to a miRNA cluster that downregulates the 
MARK1 signaling pathway, thus altering cell proliferation 
and differentiation [134]. Kim and colleagues [135] iden-
tified and validated DLGAP4, GRIN1, STX1A, CLSTN1 
and GRM4, which all function in neuronal glutamatergic 
synapses, as target genes of the recently identified BD-as-
sociated miRNA, miR-1908-5p, supporting the hypothesis 
that neuronal synapses could be a key converging pathway 
of some BD-associated protein-coding genes and miRNAs. 
A deregulation of miRNA blood expression and the dif-
ferential expression of exosomal miRNAs were recently 
observed in BD patients [136,137], which may represent 
potential peripheral biomarkers to be complemented with 
other clinical and biological features for the improvement 
of diagnostic accuracy.
Concluding remarks
The former Director of the National Institute of Mental 
Health (USA), Tom Insel, said recently: “Without biology, 
there is no treatment for mental disorders”. BD is a chron-
ic mental illness that follows a relapsing/remitting course 
requiring lifetime treatment. However, few treatments are 
available and have limited efficacy. Lack of biological mark-
ers is another difficulty in clinical practice. A growing body 
of evidence suggests that BD pathogenesis is closely related 
with cellular plasticity defects, including in brain cells abili-
ty to resist or adapt to environmental stressors (cellular re-
silience). Results obtained in the last years using postmor-
tem brain tissue from BD patients and also patient-derived 
cellular models support the hypothesis that disturbance of 
MAMs, which are crucial for determining cell fate under 
stress conditions, plays a major role in BD pathophysiology 
and that MAMs are relevant targets to develop new treat-
ments and biomarkers for early diagnosis. 
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